{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"5.7","value":"4.4"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"14","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Progression free survival per treatment arm. Progressive Disease (PD) requires one of the following, increase of greater than or equal to 25% from baseline in: Serum M-component; Urine M-component; The difference between involved and uninvolved sFLC levels; The size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II: Pomalidomide and high dose dexamethasone.\n\nCrossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician.\n\nArm D participants may be referenced separately in some Outcome Measures.","id":"OG000","title":"B: Pomalidomide and Dexamethasone"},{"description":"Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.","id":"OG001","title":"C: Pomalidomide, Dexamethasone, Cyclophosphamide"}],"paramType":"MEDIAN","populationDescription":"All Phase II Participants.","reportingStatus":"POSTED","timeFrame":"36 Months","title":"Phase II - Median Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}